LongeVC portfolio company Unnatural Products (UNP) has entered a multi-target collaboration with argenx to develop oral macrocyclic peptide therapeutics. The partnership, focused on advancing precision immunology, includes equity investment, upfront payments, and potential milestones worth over $1.5 billion. UNP’s AI-powered platform enables the design of oral macrocycles that drug previously unreachable targets, marking a new chapter for this modality.
You can read the full press release here.
You can read the full press release here.